JP7387603B2 - 活性化のための線維芽細胞と免疫細胞との相互作用及びそれらの使用 - Google Patents
活性化のための線維芽細胞と免疫細胞との相互作用及びそれらの使用 Download PDFInfo
- Publication number
- JP7387603B2 JP7387603B2 JP2020529293A JP2020529293A JP7387603B2 JP 7387603 B2 JP7387603 B2 JP 7387603B2 JP 2020529293 A JP2020529293 A JP 2020529293A JP 2020529293 A JP2020529293 A JP 2020529293A JP 7387603 B2 JP7387603 B2 JP 7387603B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- fibroblasts
- hours
- days
- section
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002950 fibroblast Anatomy 0.000 title claims description 378
- 210000002865 immune cell Anatomy 0.000 title claims description 74
- 230000003993 interaction Effects 0.000 title description 14
- 230000004913 activation Effects 0.000 title description 10
- 238000000034 method Methods 0.000 claims description 402
- 239000003795 chemical substances by application Substances 0.000 claims description 119
- 239000000203 mixture Substances 0.000 claims description 94
- 210000002966 serum Anatomy 0.000 claims description 70
- 108010074328 Interferon-gamma Proteins 0.000 claims description 65
- 210000001616 monocyte Anatomy 0.000 claims description 65
- 102000004127 Cytokines Human genes 0.000 claims description 46
- 108090000695 Cytokines Proteins 0.000 claims description 46
- 241000282414 Homo sapiens Species 0.000 claims description 46
- 239000002609 medium Substances 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 38
- 239000003102 growth factor Substances 0.000 claims description 34
- 102000003814 Interleukin-10 Human genes 0.000 claims description 29
- 108090000174 Interleukin-10 Proteins 0.000 claims description 29
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 26
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 25
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 25
- 238000004519 manufacturing process Methods 0.000 claims description 25
- 230000002491 angiogenic effect Effects 0.000 claims description 24
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 23
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 23
- 102000015696 Interleukins Human genes 0.000 claims description 21
- 108010063738 Interleukins Proteins 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 210000004700 fetal blood Anatomy 0.000 claims description 17
- 210000004623 platelet-rich plasma Anatomy 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- 108090001007 Interleukin-8 Proteins 0.000 claims description 16
- 102000004890 Interleukin-8 Human genes 0.000 claims description 16
- 108010065805 Interleukin-12 Proteins 0.000 claims description 15
- 102000013462 Interleukin-12 Human genes 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 14
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 13
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 13
- 102000004889 Interleukin-6 Human genes 0.000 claims description 13
- 108090001005 Interleukin-6 Proteins 0.000 claims description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 13
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 13
- 102000013691 Interleukin-17 Human genes 0.000 claims description 12
- 108050003558 Interleukin-17 Proteins 0.000 claims description 12
- 108010067003 Interleukin-33 Proteins 0.000 claims description 12
- 102000017761 Interleukin-33 Human genes 0.000 claims description 12
- 108090000172 Interleukin-15 Proteins 0.000 claims description 10
- 102000003812 Interleukin-15 Human genes 0.000 claims description 10
- 108010002586 Interleukin-7 Proteins 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 10
- 239000006166 lysate Substances 0.000 claims description 10
- 239000007640 basal medium Substances 0.000 claims description 8
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims description 7
- 102100037850 Interferon gamma Human genes 0.000 claims description 4
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 claims description 2
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 claims description 2
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 claims description 2
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 claims description 2
- 102100033501 Interleukin-32 Human genes 0.000 claims description 2
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 claims description 2
- 239000000710 homodimer Substances 0.000 claims description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 3
- 238000004321 preservation Methods 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 299
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 78
- 210000003289 regulatory T cell Anatomy 0.000 description 64
- 102000008070 Interferon-gamma Human genes 0.000 description 61
- 229960003130 interferon gamma Drugs 0.000 description 61
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 59
- 230000001363 autoimmune Effects 0.000 description 58
- 210000001744 T-lymphocyte Anatomy 0.000 description 57
- -1 e.g. Substances 0.000 description 57
- 230000005847 immunogenicity Effects 0.000 description 57
- 201000010099 disease Diseases 0.000 description 56
- 210000001519 tissue Anatomy 0.000 description 55
- 230000002519 immonomodulatory effect Effects 0.000 description 51
- 210000000130 stem cell Anatomy 0.000 description 42
- 210000004185 liver Anatomy 0.000 description 37
- 239000006041 probiotic Substances 0.000 description 33
- 235000018291 probiotics Nutrition 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 32
- 208000011580 syndromic disease Diseases 0.000 description 32
- 210000001185 bone marrow Anatomy 0.000 description 31
- 230000000735 allogeneic effect Effects 0.000 description 29
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 29
- 230000000694 effects Effects 0.000 description 29
- 229910052760 oxygen Inorganic materials 0.000 description 29
- 239000001301 oxygen Substances 0.000 description 29
- 230000001939 inductive effect Effects 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- 210000004698 lymphocyte Anatomy 0.000 description 25
- 102000000588 Interleukin-2 Human genes 0.000 description 24
- 108010002350 Interleukin-2 Proteins 0.000 description 24
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 24
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 24
- 210000004443 dendritic cell Anatomy 0.000 description 23
- 210000002501 natural regulatory T cell Anatomy 0.000 description 23
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 22
- 230000008929 regeneration Effects 0.000 description 22
- 238000011069 regeneration method Methods 0.000 description 22
- 230000033115 angiogenesis Effects 0.000 description 21
- 235000013406 prebiotics Nutrition 0.000 description 21
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 21
- 229960002930 sirolimus Drugs 0.000 description 21
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 21
- 102000004388 Interleukin-4 Human genes 0.000 description 20
- 108090000978 Interleukin-4 Proteins 0.000 description 20
- 210000003953 foreskin Anatomy 0.000 description 20
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 19
- 210000004204 blood vessel Anatomy 0.000 description 19
- 239000012091 fetal bovine serum Substances 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 18
- 208000007465 Giant cell arteritis Diseases 0.000 description 17
- 208000009329 Graft vs Host Disease Diseases 0.000 description 17
- 230000005784 autoimmunity Effects 0.000 description 17
- 208000024908 graft versus host disease Diseases 0.000 description 17
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 17
- 230000000529 probiotic effect Effects 0.000 description 17
- 206010043207 temporal arteritis Diseases 0.000 description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 16
- 230000002757 inflammatory effect Effects 0.000 description 16
- 230000035755 proliferation Effects 0.000 description 16
- 102000004452 Arginase Human genes 0.000 description 15
- 108700024123 Arginases Proteins 0.000 description 15
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 15
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 15
- 102100025304 Integrin beta-1 Human genes 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 208000008795 neuromyelitis optica Diseases 0.000 description 15
- 210000005259 peripheral blood Anatomy 0.000 description 15
- 239000011886 peripheral blood Substances 0.000 description 15
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 14
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 14
- 229940045513 CTLA4 antagonist Drugs 0.000 description 14
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 14
- 108010008165 Etanercept Proteins 0.000 description 14
- 206010019663 Hepatic failure Diseases 0.000 description 14
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 14
- 210000000577 adipose tissue Anatomy 0.000 description 14
- 108090000681 interleukin 20 Proteins 0.000 description 14
- 102000004114 interleukin 20 Human genes 0.000 description 14
- 231100000835 liver failure Toxicity 0.000 description 14
- 208000007903 liver failure Diseases 0.000 description 14
- 108010001517 Galectin 3 Proteins 0.000 description 13
- 102000000802 Galectin 3 Human genes 0.000 description 13
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 13
- 108010024164 HLA-G Antigens Proteins 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 13
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 13
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 13
- 238000003501 co-culture Methods 0.000 description 13
- 230000004968 inflammatory condition Effects 0.000 description 13
- 210000000056 organ Anatomy 0.000 description 13
- 208000033808 peripheral neuropathy Diseases 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 208000021866 Dressler syndrome Diseases 0.000 description 12
- 206010018364 Glomerulonephritis Diseases 0.000 description 12
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 12
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 12
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 12
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 12
- 206010046851 Uveitis Diseases 0.000 description 12
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 12
- 238000002659 cell therapy Methods 0.000 description 12
- 230000001684 chronic effect Effects 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 206010025135 lupus erythematosus Diseases 0.000 description 12
- 244000005700 microbiome Species 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 201000006417 multiple sclerosis Diseases 0.000 description 12
- 201000008383 nephritis Diseases 0.000 description 12
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 210000001778 pluripotent stem cell Anatomy 0.000 description 12
- 208000002574 reactive arthritis Diseases 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 12
- 208000008190 Agammaglobulinemia Diseases 0.000 description 11
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 11
- 102100037241 Endoglin Human genes 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 11
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 11
- 206010021143 Hypoxia Diseases 0.000 description 11
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 11
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 11
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 11
- 201000001981 dermatomyositis Diseases 0.000 description 11
- 238000011124 ex vivo culture Methods 0.000 description 11
- 210000003494 hepatocyte Anatomy 0.000 description 11
- 210000000987 immune system Anatomy 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 10
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 10
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 10
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 10
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 description 10
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 10
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 10
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 10
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 description 10
- 206010034277 Pemphigoid Diseases 0.000 description 10
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 10
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 10
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 10
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- 229960005167 everolimus Drugs 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000004936 stimulating effect Effects 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 208000023275 Autoimmune disease Diseases 0.000 description 9
- 108010074708 B7-H1 Antigen Proteins 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 9
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 9
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 9
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 9
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 9
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 9
- 208000019425 cirrhosis of liver Diseases 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 230000004761 fibrosis Effects 0.000 description 9
- 239000003862 glucocorticoid Substances 0.000 description 9
- 230000001146 hypoxic effect Effects 0.000 description 9
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 9
- 210000002826 placenta Anatomy 0.000 description 9
- 230000003169 placental effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 description 9
- 229960001940 sulfasalazine Drugs 0.000 description 9
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 9
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 9
- 229940037128 systemic glucocorticoids Drugs 0.000 description 9
- 102100022464 5'-nucleotidase Human genes 0.000 description 8
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 8
- 108010036949 Cyclosporine Proteins 0.000 description 8
- 206010048768 Dermatosis Diseases 0.000 description 8
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 8
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 8
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 8
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 8
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
- 241000186604 Lactobacillus reuteri Species 0.000 description 8
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 8
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 8
- 229960005207 auranofin Drugs 0.000 description 8
- 229960001265 ciclosporin Drugs 0.000 description 8
- 229930182912 cyclosporin Natural products 0.000 description 8
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 8
- 229960004171 hydroxychloroquine Drugs 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 239000002955 immunomodulating agent Substances 0.000 description 8
- 229940121354 immunomodulator Drugs 0.000 description 8
- 230000001506 immunosuppresive effect Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 8
- 229960000681 leflunomide Drugs 0.000 description 8
- 229960000485 methotrexate Drugs 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 208000017520 skin disease Diseases 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 210000001541 thymus gland Anatomy 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 7
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 7
- 102100022749 Aminopeptidase N Human genes 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 7
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 7
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 7
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 7
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 7
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 7
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 7
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 7
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 7
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 7
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 7
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 7
- 102100021592 Interleukin-7 Human genes 0.000 description 7
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 7
- 108090001030 Lipoproteins Proteins 0.000 description 7
- 102000004895 Lipoproteins Human genes 0.000 description 7
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 7
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 7
- DGOHFTDNMSZWDQ-UHFFFAOYSA-N N#C[Au]C#N Chemical compound N#C[Au]C#N DGOHFTDNMSZWDQ-UHFFFAOYSA-N 0.000 description 7
- 241000721454 Pemphigus Species 0.000 description 7
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 7
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 7
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 7
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 7
- 206010047115 Vasculitis Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 229960003697 abatacept Drugs 0.000 description 7
- 229960004308 acetylcysteine Drugs 0.000 description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 229960002964 adalimumab Drugs 0.000 description 7
- 229960004238 anakinra Drugs 0.000 description 7
- 229960005370 atorvastatin Drugs 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229960003115 certolizumab pegol Drugs 0.000 description 7
- 230000000139 costimulatory effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229960000403 etanercept Drugs 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 229960003765 fluvastatin Drugs 0.000 description 7
- 229960001743 golimumab Drugs 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 229960000598 infliximab Drugs 0.000 description 7
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 7
- 229940001882 lactobacillus reuteri Drugs 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 229960004844 lovastatin Drugs 0.000 description 7
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 7
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 7
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 7
- 229960003086 naltrexone Drugs 0.000 description 7
- 201000001119 neuropathy Diseases 0.000 description 7
- 230000007823 neuropathy Effects 0.000 description 7
- 229960002797 pitavastatin Drugs 0.000 description 7
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 7
- 229960002965 pravastatin Drugs 0.000 description 7
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 7
- 229960003387 progesterone Drugs 0.000 description 7
- 239000000186 progesterone Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 229960004641 rituximab Drugs 0.000 description 7
- 229960000672 rosuvastatin Drugs 0.000 description 7
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 7
- 229960002855 simvastatin Drugs 0.000 description 7
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- 229960003989 tocilizumab Drugs 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 6
- 208000026872 Addison Disease Diseases 0.000 description 6
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 206010001935 American trypanosomiasis Diseases 0.000 description 6
- 208000028185 Angioedema Diseases 0.000 description 6
- 102000009840 Angiopoietins Human genes 0.000 description 6
- 108010009906 Angiopoietins Proteins 0.000 description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 6
- 206010002961 Aplasia Diseases 0.000 description 6
- 206010003267 Arthritis reactive Diseases 0.000 description 6
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 6
- 206010071577 Autoimmune hyperlipidaemia Diseases 0.000 description 6
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 6
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 6
- 206010061666 Autonomic neuropathy Diseases 0.000 description 6
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 6
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 6
- 102100036841 C-C motif chemokine 1 Human genes 0.000 description 6
- 208000031229 Cardiomyopathies Diseases 0.000 description 6
- 208000005024 Castleman disease Diseases 0.000 description 6
- 208000024699 Chagas disease Diseases 0.000 description 6
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 6
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 6
- 208000015943 Coeliac disease Diseases 0.000 description 6
- 208000010007 Cogan syndrome Diseases 0.000 description 6
- 206010009900 Colitis ulcerative Diseases 0.000 description 6
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 6
- 206010011258 Coxsackie myocarditis Diseases 0.000 description 6
- 208000011231 Crohn disease Diseases 0.000 description 6
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 6
- 201000003883 Cystic fibrosis Diseases 0.000 description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 6
- 108700036803 Deficiency of interleukin-1 receptor antagonist Proteins 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 6
- 208000001708 Dupuytren contracture Diseases 0.000 description 6
- 201000009273 Endometriosis Diseases 0.000 description 6
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 6
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 6
- 206010015226 Erythema nodosum Diseases 0.000 description 6
- 208000004332 Evans syndrome Diseases 0.000 description 6
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 6
- 208000001640 Fibromyalgia Diseases 0.000 description 6
- 208000024869 Goodpasture syndrome Diseases 0.000 description 6
- 208000015023 Graves' disease Diseases 0.000 description 6
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 6
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 6
- 206010019263 Heart block congenital Diseases 0.000 description 6
- 101000713104 Homo sapiens C-C motif chemokine 1 Proteins 0.000 description 6
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 6
- 206010021263 IgA nephropathy Diseases 0.000 description 6
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 6
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 6
- 206010061598 Immunodeficiency Diseases 0.000 description 6
- 208000029462 Immunodeficiency disease Diseases 0.000 description 6
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 6
- 102000003810 Interleukin-18 Human genes 0.000 description 6
- 108090000171 Interleukin-18 Proteins 0.000 description 6
- 208000005615 Interstitial Cystitis Diseases 0.000 description 6
- 208000003456 Juvenile Arthritis Diseases 0.000 description 6
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 6
- 208000002260 Keloid Diseases 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 6
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 6
- 208000012309 Linear IgA disease Diseases 0.000 description 6
- 208000016604 Lyme disease Diseases 0.000 description 6
- 208000002805 Mediastinal fibrosis Diseases 0.000 description 6
- 208000027530 Meniere disease Diseases 0.000 description 6
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 6
- 201000002481 Myositis Diseases 0.000 description 6
- 206010053869 POEMS syndrome Diseases 0.000 description 6
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 6
- 208000004788 Pars Planitis Diseases 0.000 description 6
- 208000004362 Penile Induration Diseases 0.000 description 6
- 206010034464 Periarthritis Diseases 0.000 description 6
- 208000031845 Pernicious anaemia Diseases 0.000 description 6
- 208000020758 Peyronie disease Diseases 0.000 description 6
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 6
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 6
- 208000031732 Post-Lyme Disease Syndrome Diseases 0.000 description 6
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 6
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 6
- 206010036805 Progressive massive fibrosis Diseases 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 6
- 208000012322 Raynaud phenomenon Diseases 0.000 description 6
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 6
- 208000033464 Reiter syndrome Diseases 0.000 description 6
- 208000005793 Restless legs syndrome Diseases 0.000 description 6
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 6
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 6
- 206010039705 Scleritis Diseases 0.000 description 6
- 206010039710 Scleroderma Diseases 0.000 description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 description 6
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 6
- 241000194017 Streptococcus Species 0.000 description 6
- 206010042276 Subacute endocarditis Diseases 0.000 description 6
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 6
- 230000005867 T cell response Effects 0.000 description 6
- 208000001106 Takayasu Arteritis Diseases 0.000 description 6
- 206010071574 Testicular autoimmunity Diseases 0.000 description 6
- 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 6
- 108700036309 Type I Plasminogen Deficiency Proteins 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 description 6
- 206010047642 Vitiligo Diseases 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 208000004631 alopecia areata Diseases 0.000 description 6
- 210000004381 amniotic fluid Anatomy 0.000 description 6
- 206010002022 amyloidosis Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000001746 atrial effect Effects 0.000 description 6
- 208000006424 autoimmune oophoritis Diseases 0.000 description 6
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 6
- 230000003376 axonal effect Effects 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 6
- 201000004395 congenital heart block Diseases 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 6
- 206010014599 encephalitis Diseases 0.000 description 6
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 208000002980 facial hemiatrophy Diseases 0.000 description 6
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 6
- 208000007475 hemolytic anemia Diseases 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- 231100000283 hepatitis Toxicity 0.000 description 6
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 6
- 230000007813 immunodeficiency Effects 0.000 description 6
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 6
- 201000008319 inclusion body myositis Diseases 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 6
- 210000001117 keloid Anatomy 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 201000011486 lichen planus Diseases 0.000 description 6
- 206010071570 ligneous conjunctivitis Diseases 0.000 description 6
- 210000005087 mononuclear cell Anatomy 0.000 description 6
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 6
- 206010028417 myasthenia gravis Diseases 0.000 description 6
- 206010028537 myelofibrosis Diseases 0.000 description 6
- 201000003631 narcolepsy Diseases 0.000 description 6
- 208000004235 neutropenia Diseases 0.000 description 6
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 6
- 201000006292 polyarteritis nodosa Diseases 0.000 description 6
- 208000005987 polymyositis Diseases 0.000 description 6
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 6
- 201000003068 rheumatic fever Diseases 0.000 description 6
- 201000000306 sarcoidosis Diseases 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 description 6
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 6
- 208000009174 transverse myelitis Diseases 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 5
- 206010058029 Arthrofibrosis Diseases 0.000 description 5
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 5
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 5
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 5
- 208000023328 Basedow disease Diseases 0.000 description 5
- 208000009137 Behcet syndrome Diseases 0.000 description 5
- 201000006390 Brachial Plexus Neuritis Diseases 0.000 description 5
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 5
- 208000011038 Cold agglutinin disease Diseases 0.000 description 5
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 5
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 5
- 102000006354 HLA-DR Antigens Human genes 0.000 description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 description 5
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 5
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 5
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 5
- 208000021330 IgG4-related disease Diseases 0.000 description 5
- 208000031781 Immunoglobulin G4 related sclerosing disease Diseases 0.000 description 5
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 description 5
- 206010022557 Intermediate uveitis Diseases 0.000 description 5
- 206010023330 Keloid scar Diseases 0.000 description 5
- 206010024434 Lichen sclerosus Diseases 0.000 description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 5
- 102100038169 Musculin Human genes 0.000 description 5
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 description 5
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 description 5
- 206010029229 Neuralgic amyotrophy Diseases 0.000 description 5
- 206010071579 Neuronal neuropathy Diseases 0.000 description 5
- 208000003435 Optic Neuritis Diseases 0.000 description 5
- 206010031252 Osteomyelitis Diseases 0.000 description 5
- 208000004347 Postpericardiotomy Syndrome Diseases 0.000 description 5
- 230000006052 T cell proliferation Effects 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 241000223109 Trypanosoma cruzi Species 0.000 description 5
- 210000001691 amnion Anatomy 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 206010071578 autoimmune retinopathy Diseases 0.000 description 5
- 208000029407 autoimmune urticaria Diseases 0.000 description 5
- 206010003882 axonal neuropathy Diseases 0.000 description 5
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 5
- 208000000594 bullous pemphigoid Diseases 0.000 description 5
- 208000024376 chronic urticaria Diseases 0.000 description 5
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 5
- 201000003278 cryoglobulinemia Diseases 0.000 description 5
- 230000016396 cytokine production Effects 0.000 description 5
- 230000003210 demyelinating effect Effects 0.000 description 5
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 5
- 230000002449 erythroblastic effect Effects 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000004957 immunoregulator effect Effects 0.000 description 5
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 206010063344 microscopic polyangiitis Diseases 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 208000005069 pulmonary fibrosis Diseases 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 101150013553 CD40 gene Proteins 0.000 description 4
- 102100032912 CD44 antigen Human genes 0.000 description 4
- 201000003274 CINCA syndrome Diseases 0.000 description 4
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 4
- 241000193403 Clostridium Species 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 241000702421 Dependoparvovirus Species 0.000 description 4
- 241001509319 Desulfitobacterium Species 0.000 description 4
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 4
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 4
- 241000192125 Firmicutes Species 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 4
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 4
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 4
- 206010020843 Hyperthermia Diseases 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 4
- 229930010555 Inosine Natural products 0.000 description 4
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102100025305 Integrin alpha-2 Human genes 0.000 description 4
- 102100030703 Interleukin-22 Human genes 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000204031 Mycoplasma Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 108091061960 Naked DNA Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108090000028 Neprilysin Proteins 0.000 description 4
- 102000003729 Neprilysin Human genes 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 4
- 206010065159 Polychondritis Diseases 0.000 description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 108010017842 Telomerase Proteins 0.000 description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 4
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 4
- 102000013127 Vimentin Human genes 0.000 description 4
- 108010065472 Vimentin Proteins 0.000 description 4
- 210000004504 adult stem cell Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000013043 chemical agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 238000012239 gene modification Methods 0.000 description 4
- 230000005017 genetic modification Effects 0.000 description 4
- 235000013617 genetically modified food Nutrition 0.000 description 4
- 208000018090 giant cell myocarditis Diseases 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 230000036031 hyperthermia Effects 0.000 description 4
- 230000002584 immunomodulator Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 229960003786 inosine Drugs 0.000 description 4
- 108010074108 interleukin-21 Proteins 0.000 description 4
- 210000004153 islets of langerhan Anatomy 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 230000000737 periodic effect Effects 0.000 description 4
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 208000009169 relapsing polychondritis Diseases 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 208000010157 sclerosing cholangitis Diseases 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 230000003614 tolerogenic effect Effects 0.000 description 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 4
- 210000003954 umbilical cord Anatomy 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 210000005048 vimentin Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 3
- 108010084313 CD58 Antigens Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000009386 Experimental Arthritis Diseases 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000007563 Galectins Human genes 0.000 description 3
- 108010046569 Galectins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019939 Herpes gestationis Diseases 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- 101000994378 Homo sapiens Integrin alpha-3 Proteins 0.000 description 3
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 3
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 3
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 3
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- 102100032819 Integrin alpha-3 Human genes 0.000 description 3
- 102100032818 Integrin alpha-4 Human genes 0.000 description 3
- 102100025390 Integrin beta-2 Human genes 0.000 description 3
- 102100032999 Integrin beta-3 Human genes 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 210000004322 M2 macrophage Anatomy 0.000 description 3
- 208000021642 Muscular disease Diseases 0.000 description 3
- 201000009623 Myopathy Diseases 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 3
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 3
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 206010064115 Polyglandular autoimmune syndrome type III Diseases 0.000 description 3
- 208000032749 Pregnancy Diseases 0.000 description 3
- 102100040120 Prominin-1 Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101710150336 Protein Rex Proteins 0.000 description 3
- 102000003800 Selectins Human genes 0.000 description 3
- 108090000184 Selectins Proteins 0.000 description 3
- 101150052863 THY1 gene Proteins 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 3
- 210000004241 Th2 cell Anatomy 0.000 description 3
- 102100026966 Thrombomodulin Human genes 0.000 description 3
- 108010079274 Thrombomodulin Proteins 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000002187 allostimulatory effect Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 229940028885 interleukin-4 Drugs 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000001776 parthenogenetic effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000004952 protein activity Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000008458 response to injury Effects 0.000 description 3
- 230000003938 response to stress Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 2
- KFEUJDWYNGMDBV-UHFFFAOYSA-N (N-Acetyl)-glucosamin-4-beta-galaktosid Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 KFEUJDWYNGMDBV-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 description 2
- 229940062827 2'-fucosyllactose Drugs 0.000 description 2
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 description 2
- AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 description 2
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 2
- 101150097308 ARD1 gene Proteins 0.000 description 2
- 241001420322 Acetanaerobacterium Species 0.000 description 2
- 241001495178 Acetivibrio Species 0.000 description 2
- 102100038740 Activator of RNA decay Human genes 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 2
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 2
- 241001147780 Alicyclobacillus Species 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000197729 Alkaliphilus Species 0.000 description 2
- 241000147157 Ammonifex Species 0.000 description 2
- 241001147782 Amphibacillus Species 0.000 description 2
- 241000079561 Anaerofustis Species 0.000 description 2
- 241001227086 Anaerostipes Species 0.000 description 2
- 241001013579 Anaerotruncus Species 0.000 description 2
- 241001626813 Anoxybacillus Species 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 241001202853 Blautia Species 0.000 description 2
- 241001148534 Brachyspira Species 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 241000555281 Brevibacillus Species 0.000 description 2
- 241000249959 Bulleidia Species 0.000 description 2
- 241001557932 Butyricicoccus Species 0.000 description 2
- 241000605902 Butyrivibrio Species 0.000 description 2
- 102100024210 CD166 antigen Human genes 0.000 description 2
- 102100025222 CD63 antigen Human genes 0.000 description 2
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 2
- 241001058118 Caldanaerobacter Species 0.000 description 2
- 241000178334 Caldicellulosiruptor Species 0.000 description 2
- 241000620141 Carboxydothermus Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 241000946390 Catenibacterium Species 0.000 description 2
- 206010008685 Chondritis Diseases 0.000 description 2
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 2
- 241001430149 Clostridiaceae Species 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- 241000047490 Cohnella Species 0.000 description 2
- 241001464956 Collinsella Species 0.000 description 2
- 241001443882 Coprobacillus Species 0.000 description 2
- 241001464948 Coprococcus Species 0.000 description 2
- 241001445332 Coxiella <snail> Species 0.000 description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 2
- 241001143296 Deferribacteres <phylum> Species 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- 241001313301 Dendrosporobacter Species 0.000 description 2
- 241001338026 Desulfosporosinus Species 0.000 description 2
- 241000186541 Desulfotomaculum Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 101100270214 Dictyostelium discoideum natA gene Proteins 0.000 description 2
- 241001657509 Eggerthella Species 0.000 description 2
- 241000186811 Erysipelothrix Species 0.000 description 2
- 241000609971 Erysipelotrichaceae Species 0.000 description 2
- 241001350695 Ethanoligenens Species 0.000 description 2
- 241000186394 Eubacterium Species 0.000 description 2
- 101150021185 FGF gene Proteins 0.000 description 2
- 241001608234 Faecalibacterium Species 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 241000178967 Filifactor Species 0.000 description 2
- 108010040721 Flagellin Proteins 0.000 description 2
- 241000662772 Flavonifractor Species 0.000 description 2
- 241000204479 Flexistipes Species 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 241000011639 Fulvimonas Species 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 2
- 102100036519 Gastrin-releasing peptide Human genes 0.000 description 2
- 241001185600 Gemmiger Species 0.000 description 2
- 241000626621 Geobacillus Species 0.000 description 2
- 241001464794 Gloeobacter Species 0.000 description 2
- 101150106864 HR gene Proteins 0.000 description 2
- 241000144305 Halobacteroides Species 0.000 description 2
- 241000207155 Heliobacterium Species 0.000 description 2
- 241001628319 Heliophilum Species 0.000 description 2
- 241001326442 Heliorestis Species 0.000 description 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 2
- 241000862469 Holdemania Species 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 2
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 2
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101000595198 Homo sapiens Podocalyxin Proteins 0.000 description 2
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000339806 Hydrogenoanaerobacterium Species 0.000 description 2
- 208000031814 IgA Vasculitis Diseases 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 241000579722 Kocuria Species 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 241001233595 Lachnobacterium Species 0.000 description 2
- 241001134638 Lachnospira Species 0.000 description 2
- 241001112693 Lachnospiraceae Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 241000589902 Leptospira Species 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 241000605635 Lutispora Species 0.000 description 2
- 241000568397 Lysinibacillus Species 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241001046559 Marvinbryantia Species 0.000 description 2
- 241001430197 Mollicutes Species 0.000 description 2
- 241000178985 Moorella Species 0.000 description 2
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 2
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 description 2
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 description 2
- HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 description 2
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 208000029067 Neuromyelitis optica spectrum disease Diseases 0.000 description 2
- 241000187654 Nocardia Species 0.000 description 2
- 241001072230 Oceanobacillus Species 0.000 description 2
- 241000203287 Orenia Species 0.000 description 2
- 241000843248 Oscillibacter Species 0.000 description 2
- 241000266824 Oscillospira Species 0.000 description 2
- 241000178984 Oxalophagus Species 0.000 description 2
- 241000178986 Oxobacter Species 0.000 description 2
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 2
- 241000179039 Paenibacillus Species 0.000 description 2
- 241001446614 Papillibacter Species 0.000 description 2
- 241001559000 Pelospora Species 0.000 description 2
- 241001425545 Pelotomaculum Species 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 206010034576 Peripheral ischaemia Diseases 0.000 description 2
- 102100036031 Podocalyxin Human genes 0.000 description 2
- 229920001100 Polydextrose Polymers 0.000 description 2
- 206010036072 Polyglandular autoimmune syndrome type I Diseases 0.000 description 2
- 206010036073 Polyglandular autoimmune syndrome type II Diseases 0.000 description 2
- 241000169380 Propionispora Species 0.000 description 2
- 241000280572 Pseudoflavonifractor Species 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 241001662542 Robinsoniella Species 0.000 description 2
- 241000605947 Roseburia Species 0.000 description 2
- 241000192031 Ruminococcus Species 0.000 description 2
- 241000187792 Saccharomonospora Species 0.000 description 2
- 241000192023 Sarcina Species 0.000 description 2
- 241000549372 Solobacterium Species 0.000 description 2
- 241000168515 Sporobacter Species 0.000 description 2
- 241000605066 Sporohalobacter Species 0.000 description 2
- 241000204117 Sporolactobacillus Species 0.000 description 2
- 241000204388 Sporomusa Species 0.000 description 2
- 241000186547 Sporosarcina Species 0.000 description 2
- 241000969788 Sporotomaculum Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 241001136694 Subdoligranulum Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000498538 Syntrophobotulus Species 0.000 description 2
- 241001656784 Syntrophococcus Species 0.000 description 2
- 241000606017 Syntrophomonas Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 241000846120 Terribacillus Species 0.000 description 2
- 241000186339 Thermoanaerobacter Species 0.000 description 2
- 241001647802 Thermobifida Species 0.000 description 2
- 241000035670 Thermosinus Species 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 206010067774 Tumour necrosis factor receptor-associated periodic syndrome Diseases 0.000 description 2
- 241001425419 Turicibacter Species 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 229920000392 Zymosan Polymers 0.000 description 2
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 2
- 230000000961 alloantigen Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 229920000617 arabinoxylan Polymers 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 229940046731 calcineurin inhibitors Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004970 cd4 cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012710 chemistry, manufacturing and control Methods 0.000 description 2
- 208000003167 cholangitis Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000005956 cytoplasmic translocation Effects 0.000 description 2
- 230000007402 cytotoxic response Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000032459 dedifferentiation Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 230000004041 dendritic cell maturation Effects 0.000 description 2
- 210000005258 dental pulp stem cell Anatomy 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 108700014844 flt3 ligand Proteins 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000003259 immunoinhibitory effect Effects 0.000 description 2
- 231100001039 immunological change Toxicity 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000014828 interferon-gamma production Effects 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 2
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000004066 metabolic change Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960002169 plerixafor Drugs 0.000 description 2
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 239000001259 polydextrose Substances 0.000 description 2
- 235000013856 polydextrose Nutrition 0.000 description 2
- 229940035035 polydextrose Drugs 0.000 description 2
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000035752 proliferative phase Effects 0.000 description 2
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 229950010550 resiquimod Drugs 0.000 description 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000000717 sertoli cell Anatomy 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- DMWMUMWKGKGSNW-OPMCLZTFSA-N (2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-[(2R)-2,3-di(hexadecanoyloxy)propyl]sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](CSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O)OC(=O)CCCCCCCCCCCCCCC DMWMUMWKGKGSNW-OPMCLZTFSA-N 0.000 description 1
- OEDPHAKKZGDBEV-GFPBKZJXSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CCCCCCCCCCCCCCC)CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC OEDPHAKKZGDBEV-GFPBKZJXSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- 108020005097 23S Ribosomal RNA Proteins 0.000 description 1
- 102100024406 60S ribosomal protein L15 Human genes 0.000 description 1
- 102100028348 60S ribosomal protein L26 Human genes 0.000 description 1
- DVKQVRZMKBDMDH-UUOKFMHZSA-N 8-Br-cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DVKQVRZMKBDMDH-UUOKFMHZSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000006267 AMP Deaminase Human genes 0.000 description 1
- 108700016228 AMP deaminases Proteins 0.000 description 1
- 241000204396 Acetonema Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000195580 Anaerosporobacter Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010062542 Arterial insufficiency Diseases 0.000 description 1
- 101710115233 Arylsulfatase D Proteins 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 102100032487 Beta-mannosidase Human genes 0.000 description 1
- 102100025991 Betaine-homocysteine S-methyltransferase 1 Human genes 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 102100036302 C-C chemokine receptor type 6 Human genes 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 102000053028 CD36 Antigens Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 102100029761 Cadherin-5 Human genes 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- 241000178972 Caloramator Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 102400001321 Cathepsin L Human genes 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 241000498849 Chlamydiales Species 0.000 description 1
- 208000016216 Choristoma Diseases 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- 102000015612 Complement 3b Receptors Human genes 0.000 description 1
- 108010024114 Complement 3b Receptors Proteins 0.000 description 1
- 102000003706 Complement factor D Human genes 0.000 description 1
- 108090000059 Complement factor D Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 description 1
- 102100033672 Deleted in azoospermia-like Human genes 0.000 description 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241001143779 Dorea Species 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 101710096804 Dual specificity protein phosphatase 10 Proteins 0.000 description 1
- 102100037569 Dual specificity protein phosphatase 10 Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- 102100039247 ETS-related transcription factor Elf-4 Human genes 0.000 description 1
- 101100243360 Entamoeba histolytica PEPCK1 gene Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102100029777 Eukaryotic translation initiation factor 3 subunit M Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710088083 Glomulin Proteins 0.000 description 1
- 102100036255 Glucose-6-phosphatase 2 Human genes 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 1
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101001080179 Homo sapiens 60S ribosomal protein L26 Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101001016707 Homo sapiens Beta-mannosidase Proteins 0.000 description 1
- 101000933413 Homo sapiens Betaine-homocysteine S-methyltransferase 1 Proteins 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 1
- 101000871280 Homo sapiens Deleted in azoospermia-like Proteins 0.000 description 1
- 101001107084 Homo sapiens E3 ubiquitin-protein ligase RNF5 Proteins 0.000 description 1
- 101000813135 Homo sapiens ETS-related transcription factor Elf-4 Proteins 0.000 description 1
- 101001012700 Homo sapiens Eukaryotic translation initiation factor 3 subunit M Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101000930907 Homo sapiens Glucose-6-phosphatase 2 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 1
- 101001112162 Homo sapiens Kinetochore protein NDC80 homolog Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000982000 Homo sapiens N-alpha-acetyltransferase 15, NatA auxiliary subunit Proteins 0.000 description 1
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 description 1
- 101000996663 Homo sapiens Neurotrophin-4 Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000804728 Homo sapiens Protein Wnt-2b Proteins 0.000 description 1
- 101001092160 Homo sapiens Regulator of G-protein signaling 10 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000906283 Homo sapiens Solute carrier family 2, facilitated glucose transporter member 1 Proteins 0.000 description 1
- 101000661600 Homo sapiens Steryl-sulfatase Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 1
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- 101710123134 Ice-binding protein Proteins 0.000 description 1
- 101710082837 Ice-structuring protein Proteins 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100025323 Integrin alpha-1 Human genes 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 description 1
- 102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- 208000005168 Intussusception Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 102100023890 Kinetochore protein NDC80 homolog Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241000122535 Lachnoanaerobaculum Species 0.000 description 1
- 241001309423 Lactonifactor Species 0.000 description 1
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
- 102000017095 Leukocyte Common Antigens Human genes 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 101150001441 MANBA gene Proteins 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102000013013 Member 2 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- 208000004535 Mesenteric Ischemia Diseases 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100032975 Myosin-1 Human genes 0.000 description 1
- 101710204036 Myosin-1 Proteins 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 108010056296 N-Terminal Acetyltransferases Proteins 0.000 description 1
- 102100026781 N-alpha-acetyltransferase 15, NatA auxiliary subunit Human genes 0.000 description 1
- 101150026563 NR4A2 gene Proteins 0.000 description 1
- 101150111783 NTRK1 gene Proteins 0.000 description 1
- 102100035487 Nectin-3 Human genes 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 1
- 108050000588 Neurogenic differentiation factor 1 Proteins 0.000 description 1
- 102100033857 Neurotrophin-4 Human genes 0.000 description 1
- 101150115192 OLIG1 gene Proteins 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010077077 Osteonectin Proteins 0.000 description 1
- 102000009890 Osteonectin Human genes 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 101150039326 PCK1 gene Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 102100034796 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 108090000983 Ribosomal protein L15 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000095588 Ruminococcaceae Species 0.000 description 1
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 102100023980 Signal transducer and activator of transcription 6 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010043267 Sp7 Transcription Factor Proteins 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000123710 Sutterella Species 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100033142 Transcription factor 20 Human genes 0.000 description 1
- 101710119730 Transcription factor 20 Proteins 0.000 description 1
- 102100032317 Transcription factor Sp7 Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102000003932 Transgelin Human genes 0.000 description 1
- 108090000333 Transgelin Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
- 101150037984 UBE2D3 gene Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 108010018828 cadherin 5 Proteins 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000033630 chronic polyneuropathy Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 210000004544 dc2 Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000004489 deciduous teeth Anatomy 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000000604 fetal stem cell Anatomy 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002344 gold compounds Chemical class 0.000 description 1
- 101150086609 groEL2 gene Proteins 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 102000054458 human STS Human genes 0.000 description 1
- 230000002977 hyperthermial effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229940124669 imidazoquinoline Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000010599 interleukin-33 production Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000008222 ischemic colitis Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010051618 macrophage stimulatory lipopeptide 2 Proteins 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000013411 master cell bank Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000033064 perforin production Effects 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000037923 polyvascular disease Diseases 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000006824 pyrimidine synthesis Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000030100 regulation of tryptophan metabolic process Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000020874 response to hypoxia Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- KNUXHTWUIVMBBY-JRJYXWDASA-N rintatolimod Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 KNUXHTWUIVMBBY-JRJYXWDASA-N 0.000 description 1
- 229950006564 rintatolimod Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000026676 system process Effects 0.000 description 1
- 230000009392 systemic autoimmunity Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002568 urticarial effect Effects 0.000 description 1
- 230000007556 vascular defect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000009614 wildtype growth Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1157—Monocytes, macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023137037A JP2023159370A (ja) | 2017-11-29 | 2023-08-25 | 活性化のための線維芽細胞と免疫細胞との相互作用及びそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762591858P | 2017-11-29 | 2017-11-29 | |
| US62/591,858 | 2017-11-29 | ||
| PCT/US2018/063001 WO2019108756A1 (en) | 2017-11-29 | 2018-11-29 | Interaction of fibroblasts and immune cells for activation and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023137037A Division JP2023159370A (ja) | 2017-11-29 | 2023-08-25 | 活性化のための線維芽細胞と免疫細胞との相互作用及びそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021503923A JP2021503923A (ja) | 2021-02-15 |
| JP2021503923A5 JP2021503923A5 (enExample) | 2022-01-04 |
| JP7387603B2 true JP7387603B2 (ja) | 2023-11-28 |
Family
ID=66665803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529293A Active JP7387603B2 (ja) | 2017-11-29 | 2018-11-29 | 活性化のための線維芽細胞と免疫細胞との相互作用及びそれらの使用 |
| JP2023137037A Pending JP2023159370A (ja) | 2017-11-29 | 2023-08-25 | 活性化のための線維芽細胞と免疫細胞との相互作用及びそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023137037A Pending JP2023159370A (ja) | 2017-11-29 | 2023-08-25 | 活性化のための線維芽細胞と免疫細胞との相互作用及びそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12233094B2 (enExample) |
| EP (1) | EP3716988A4 (enExample) |
| JP (2) | JP7387603B2 (enExample) |
| CN (1) | CN111601606A (enExample) |
| AU (1) | AU2018375151B2 (enExample) |
| CA (1) | CA3083354A1 (enExample) |
| WO (1) | WO2019108756A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018132594A1 (en) * | 2017-01-11 | 2018-07-19 | Spinalcyte, Llc | Methods of enhancing fibroblast therapeutic activity |
| AU2018254498B2 (en) | 2017-04-19 | 2023-08-03 | Figene, Llc | Stimulation of angiogenesis by fibroblast derived exosomes |
| US11959102B2 (en) * | 2017-12-20 | 2024-04-16 | Figene, Llc | Augmentation of fibroblast regenerative activity |
| EP3843758A4 (en) * | 2018-08-27 | 2022-06-08 | Figene, LLC | CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR THE TREATMENT OF CANCER |
| US12257286B2 (en) | 2018-10-31 | 2025-03-25 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12624086B2 (en) | 2018-10-31 | 2026-05-12 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| JP2022506683A (ja) | 2018-11-04 | 2022-01-17 | フィジーン、エルエルシー | 膵臓移植のファシリテーターとして繊維芽細胞を用いる１型糖尿病の治療方法および組成物 |
| EP3873503B1 (en) | 2018-11-04 | 2024-07-24 | Figene, LLC | Treatment of cachexia using fibroblast cells and products thereof |
| CN109837250B (zh) * | 2019-01-15 | 2021-10-12 | 中国农业科学院兰州兽医研究所 | 羔羊睾丸支持细胞永生化细胞系及其建立方法和应用 |
| WO2020150567A1 (en) * | 2019-01-17 | 2020-07-23 | Figene, Llc | Fibroblasts and microvesicles thereof for reduction of toxicity associated with cancer immunotherapy |
| WO2020243504A1 (en) * | 2019-05-31 | 2020-12-03 | Figene, Llc | Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis |
| EP3982984A4 (en) * | 2019-06-12 | 2023-07-12 | Figene, LLC | INCREASE OF THERAPEUTIC ACTIVITY OF FIBROBLAST BY RNA |
| AU2020302908A1 (en) * | 2019-06-28 | 2022-02-24 | Figene, Llc | Administration of fibroblasts and derivatives thereof for treatment of type 2 diabetes |
| US12648968B2 (en) | 2019-09-09 | 2026-06-09 | Spinalcyte Llc | Fibroblast and fibroblast-immunocyte combinations for treatment of subconcussive- and concussive-associated neurological damage |
| WO2021076674A1 (en) * | 2019-10-15 | 2021-04-22 | Figene, Llc | Fibroblast-based immunotherapy of graves disease |
| EP4051689A4 (en) * | 2019-11-01 | 2023-11-29 | Figene, LLC | FIBROBLAST THERAPY TO TREAT SCLEROSING CHOLANGITIS |
| CN115297873A (zh) * | 2019-11-08 | 2022-11-04 | 梅约医学教育与研究基金会 | 利用工程化改造的间充质干细胞治疗炎症和退行性疾病的方法和物质 |
| WO2021097434A1 (en) * | 2019-11-15 | 2021-05-20 | Figene, Llc | Fibroblast therapy for inflammatory bowel disease |
| US12576112B2 (en) | 2019-12-26 | 2026-03-17 | Spinalcyte Llc | Inhibition of TNF-alpha by fibroblasts and fibroblast exosomes |
| AU2020412623A1 (en) | 2019-12-26 | 2022-07-14 | Figene, Llc | Prevention and treatment of kidney failure by administration of fibroblasts and products thereof |
| US20230026352A1 (en) | 2019-12-26 | 2023-01-26 | Figene, Llc | Suppression of interleukin-17 production and inhibition of th17 cell generation by fibroblasts and products thereof |
| RU2727751C1 (ru) * | 2020-01-09 | 2020-07-23 | Сергей Николаевич Лепетунов | Способ продления безрецидивного периода интерстициального цистита |
| EP4117688A4 (en) * | 2020-03-13 | 2024-06-12 | Figene, LLC | GENERATING AUTOIMMUNE-INHIBITING T CELLS THROUGH FIBROBLAST-MEDIATED FORMATION |
| WO2021202031A1 (en) * | 2020-03-30 | 2021-10-07 | Figene, Llc | Peptides and adjuvants for augmentation of fibroblast therapy for coronavirus |
| EP4142751A4 (en) * | 2020-04-01 | 2025-01-08 | Figene, LLC | Fibroblast mediated expansion and augmentation of immune regulatory cells for treatment of acute respiratory distress syndrome (ards) |
| IL297366A (en) | 2020-04-20 | 2022-12-01 | Duogenic Stemcells Corp | Modified macrophages, preparations and uses thereof |
| JP2023524679A (ja) * | 2020-04-30 | 2023-06-13 | フィジーン、エルエルシー | 癌線維芽細胞を標的化するための免疫療法の方法および組成物 |
| US20230248777A1 (en) * | 2020-05-29 | 2023-08-10 | Figene, Llc | Augmentation of fibroblast cell therapy efficacy by microbiome manipulation |
| CN111643526A (zh) * | 2020-07-14 | 2020-09-11 | 贵州金元泰生物科技有限公司 | 一种用于延缓卵巢衰老及防治老年痴呆和抑郁的间充质干细胞制剂 |
| WO2022016184A1 (en) * | 2020-07-14 | 2022-01-20 | Figene, Llc | Augmentation of fibroblast therapeutic activity by complement blockade and/or inhibition |
| US20240238271A1 (en) * | 2020-11-25 | 2024-07-18 | Shanghai Juncell Therapeutics Co., Ltd. | Pharmaceutical composition for enhancing cell killing, and use thereof |
| US20240000854A1 (en) * | 2020-12-04 | 2024-01-04 | PRIMORIS THERAPEUTICS Co., Ltd. | Method for preparing high-concentration stem cell exosomes with enhanced anti-inflammatory and regenerative functions using lipopolysaccharide and lipoteichoic acid |
| CN112553155A (zh) * | 2020-12-28 | 2021-03-26 | 山东省齐鲁干细胞工程有限公司 | 一种脐带血间充质干细胞培养方法 |
| CA3206049A1 (en) * | 2021-02-23 | 2022-09-01 | John Cho | Methods for expanding regulatory t cells |
| CN113203781B (zh) * | 2021-05-13 | 2022-05-31 | 桂林电子科技大学 | 一种非诊断目的基于RGO-CS-Hemin@Pt NPs纳米材料和适配体检测GPC3的方法 |
| CN113519459B (zh) * | 2021-06-11 | 2022-03-25 | 中国科学院合肥物质科学研究院 | 一种采用调节肝细胞ros水平的磁场发生装置在调节人/鼠肝细胞氧化应激中的应用 |
| CN113584193B (zh) * | 2021-07-06 | 2023-07-28 | 中南大学湘雅医院 | 毛螺菌属作为评估慢性自发性荨麻疹患者抗组胺药物疗效的标志物的应用 |
| US20250092366A1 (en) * | 2021-07-20 | 2025-03-20 | Efm Biotech Inc. | Proteolytic Enzymes for Cell Culture Media |
| CN113736737B (zh) * | 2021-09-18 | 2023-09-08 | 四川大学华西医院 | 一种原代胶质瘤相关成纤维细胞培养方法 |
| WO2023075623A1 (en) * | 2021-10-26 | 2023-05-04 | Ineb (Instituto Nacional De Engenharia Biomédica) | Macrophage phenoypes for use in the treatment of intravertebral discs |
| US20230158080A1 (en) * | 2021-11-22 | 2023-05-25 | Spinalcyte, Llc | Hormonal manipulation of fibroblast therapeutic activity |
| KR20230099677A (ko) * | 2021-12-27 | 2023-07-04 | 주식회사 진켐 | 신규한 메토트렉세이트 결합체와 이의 용도 |
| CN114213540B (zh) * | 2022-02-22 | 2022-07-01 | 北京大学人民医院 | 一组用于髓系肿瘤免疫分型的抗体组合物及其应用 |
| WO2023224923A2 (en) * | 2022-05-16 | 2023-11-23 | The Regents Of The University Of California | Engineered cells and methods of use |
| CN115590887B (zh) * | 2022-10-17 | 2026-04-03 | 厦门大学 | 诱导成纤维细胞呈现免疫抑制表型的方法 |
| CN116554348A (zh) * | 2023-04-03 | 2023-08-08 | 上海交通大学医学院附属瑞金医院 | Gpc3-car-t在治疗特发性肺纤维化中的应用 |
| WO2024218715A1 (en) | 2023-04-19 | 2024-10-24 | Btl Healthcare Technologies A.S. | Culture media based on protein hydrolysate and a process for preparing thereof |
| WO2025015101A1 (en) * | 2023-07-11 | 2025-01-16 | Fibrobiologics, Inc. | Therapeutic use of fibroblasts for the treatment of psoriasis |
| KR20250023295A (ko) * | 2023-08-08 | 2025-02-18 | 주식회사 현대메디텍 | N-아세틸시스테인(nac)을 이용한 편도 유래 중간엽 줄기세포의 배양방법 |
| CN117147817B (zh) * | 2023-08-25 | 2025-11-18 | 上海艾棵颂生物科技有限公司 | 多能干细胞来源小细胞外囊泡的特征性标志物组合及其应用 |
| CN116831234A (zh) * | 2023-09-01 | 2023-10-03 | 成都铁骑力士饲料有限公司 | 一种缓解保育猪热应激的营养功能包及其制备方法和应用 |
| US12668774B2 (en) | 2023-10-12 | 2026-06-30 | Btl Healthcare Technologies A.S. | Product, system and method of cell cultivation |
| CN118165932A (zh) * | 2023-10-18 | 2024-06-11 | 北京细胞治疗集团有限公司 | 一种car-t细胞的制备方法 |
| CN117683708A (zh) * | 2023-10-26 | 2024-03-12 | 中国人民解放军总医院第一医学中心 | 用于治疗免疫相关性肾病的药物 |
| AU2025209928A1 (en) * | 2024-01-17 | 2026-07-30 | Newsouth Innovations Pty Limited | Apparatus for production of engineered cells |
| WO2025207662A1 (en) * | 2024-03-25 | 2025-10-02 | Fibrobiologics, Inc. | Therapeutic use of fibroblasts for the treatment of systemic lupus erythematosus |
| CN118045104A (zh) * | 2024-04-03 | 2024-05-17 | 椎元医学技术(上海)有限公司 | 一种成纤维细胞制剂及其在制备预防增生性脊柱炎的药物中的应用 |
| US20250312383A1 (en) * | 2024-04-05 | 2025-10-09 | Stemcyte, Inc. | Human umbilical cord blood for use in alleviating fatigue |
| CN118655199B (zh) * | 2024-08-19 | 2024-12-24 | 四川菊乐食品股份有限公司 | 一种细胞印迹电化学传感器的制备方法及利用其快速定量检测乳制品中乳酸菌的方法 |
| WO2026092339A1 (zh) * | 2024-10-28 | 2026-05-07 | 苏州血霁生物科技有限公司 | Mkp增殖分化方法及其应用 |
| CN119592507A (zh) * | 2024-12-03 | 2025-03-11 | 哈尔滨优莱福生物科技有限公司 | 一种人外周血调节性t细胞的体外扩增试剂盒及其使用方法和应用 |
| CN119386163B (zh) * | 2025-01-03 | 2025-03-07 | 北京益华生物科技有限公司 | 一种提高细胞疗法再生的药物组合物及其应用 |
| CN119638837B (zh) * | 2025-01-21 | 2025-12-30 | 广东拓普灵生物医药科技有限公司 | 一种人脐带间充质干细胞扩增培养基及培养方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002529508A (ja) | 1998-11-13 | 2002-09-10 | オシリス セラピューティクス，インコーポレイテッド | 移植における免疫応答抑制のための線維芽細胞または線維芽細胞からの上澄みを使用する方法とその組成物 |
| JP2013507945A (ja) | 2009-10-23 | 2013-03-07 | セルルエリク エス．エー． | 免疫調節活性を有する細胞集団、その製造方法及び使用 |
| WO2016068217A1 (ja) | 2014-10-29 | 2016-05-06 | 国立大学法人山口大学 | 末梢血単核球又は末梢血単核球より分泌される因子を伴う線維芽細胞を含む細胞シート |
| US20170196951A1 (en) | 2015-01-09 | 2017-07-13 | Batu Biologics, Inc. | Polyvalent anti-tumor fibroblast vaccine |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5032508A (en) * | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| CN1234417A (zh) | 1998-11-05 | 1999-11-10 | 褚炎明 | 一种彩色发光塑料 |
| WO2001023421A2 (en) * | 1999-09-30 | 2001-04-05 | Corixa Corporation | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| CA2422586A1 (en) * | 2000-09-15 | 2002-03-21 | The Scripps Research Institute | Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| US7011965B2 (en) | 2001-03-09 | 2006-03-14 | Regents Of The University Of Minnesota | Compositions and methods for stimulating wound healing and fibroblast proliferation |
| AU2003216288B2 (en) * | 2002-02-13 | 2009-09-24 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
| TWI288779B (en) * | 2002-03-28 | 2007-10-21 | Blasticon Biotech Forschung | Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| US20080063652A1 (en) * | 2004-03-29 | 2008-03-13 | Cytomatrix, Llc | Methods for Production of Regulatory T Cells and Uses Thereof |
| WO2006026730A2 (en) * | 2004-08-30 | 2006-03-09 | Iken Tissue Therapeutics, Inc. | Cultured three dimensional tissues and uses thereof |
| US20070059824A1 (en) * | 2005-09-12 | 2007-03-15 | Yong Zhao | Human umbilical cord blood-derived pluripotent fibroblast-like-macrophages |
| JP2009508650A (ja) * | 2005-09-21 | 2009-03-05 | ダスク テクノロジーズ， エルエルシー | 臓器および組織機能のための方法および組成 |
| FI20065514A0 (fi) * | 2006-08-16 | 2006-08-16 | Licentia Oy | Aktivoidut fibroblastit kudosvaurioiden hoitamiseksi |
| EP1944361A1 (en) * | 2007-01-11 | 2008-07-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for expanding monocytes |
| KR100995340B1 (ko) | 2007-11-19 | 2010-11-19 | 재단법인서울대학교산학협력재단 | 자연 살해 ｔ 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신 |
| CA2771900A1 (en) * | 2009-08-22 | 2011-03-10 | Charles Knezevich | Tumoricidal, bactericidal, or viricidal macrophage activation |
| AU2012300221A1 (en) * | 2011-08-29 | 2014-04-17 | Safeguard Cell Technology Inc. | Isolating and therapeutic use of perivascular medicinal cells |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| JP6367836B2 (ja) * | 2013-02-07 | 2018-08-01 | ザ ジェネラル ホスピタル コーポレイション | Ｔ制御性細胞の増殖または枯渇方法 |
| JP6437467B2 (ja) * | 2013-03-14 | 2018-12-19 | ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． | 線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法 |
| ES2834129T3 (es) * | 2013-06-04 | 2021-06-16 | Selecta Biosciences Inc | Administración repetida de agentes inmunoterapéuticos específicos de antígeno no inmunosupresores |
| WO2015189063A1 (en) * | 2014-06-10 | 2015-12-17 | Mesoblast International Sàrl | Treatment of immune disorders |
| CN107208055B (zh) * | 2015-01-17 | 2021-06-15 | 浙江大学 | 引起免疫原性反应降低的被修饰细胞 |
| KR101867942B1 (ko) * | 2015-10-22 | 2018-06-20 | 가톨릭대학교 산학협력단 | 바이러스 항원 특이적인 t 세포의 유도 및 증식 방법 |
| TWI612057B (zh) * | 2015-10-28 | 2018-01-21 | 大江生醫股份有限公司 | 可促進傷口癒合、膠原蛋白增生、血管新生、活化免疫細胞並降低傷口感染之胜肽及其應用 |
-
2018
- 2018-11-29 EP EP18884660.4A patent/EP3716988A4/en active Pending
- 2018-11-29 CA CA3083354A patent/CA3083354A1/en active Pending
- 2018-11-29 US US16/765,060 patent/US12233094B2/en active Active
- 2018-11-29 AU AU2018375151A patent/AU2018375151B2/en active Active
- 2018-11-29 JP JP2020529293A patent/JP7387603B2/ja active Active
- 2018-11-29 WO PCT/US2018/063001 patent/WO2019108756A1/en not_active Ceased
- 2018-11-29 CN CN201880086376.5A patent/CN111601606A/zh active Pending
-
2023
- 2023-08-25 JP JP2023137037A patent/JP2023159370A/ja active Pending
-
2025
- 2025-01-14 US US19/020,418 patent/US20250144151A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002529508A (ja) | 1998-11-13 | 2002-09-10 | オシリス セラピューティクス，インコーポレイテッド | 移植における免疫応答抑制のための線維芽細胞または線維芽細胞からの上澄みを使用する方法とその組成物 |
| JP2013507945A (ja) | 2009-10-23 | 2013-03-07 | セルルエリク エス．エー． | 免疫調節活性を有する細胞集団、その製造方法及び使用 |
| WO2016068217A1 (ja) | 2014-10-29 | 2016-05-06 | 国立大学法人山口大学 | 末梢血単核球又は末梢血単核球より分泌される因子を伴う線維芽細胞を含む細胞シート |
| US20170196951A1 (en) | 2015-01-09 | 2017-07-13 | Batu Biologics, Inc. | Polyvalent anti-tumor fibroblast vaccine |
Non-Patent Citations (1)
| Title |
|---|
| Journal of Investigative Dermatology，2010年，Vol.130，pp.444-454 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3716988A4 (en) | 2021-12-15 |
| US20250144151A1 (en) | 2025-05-08 |
| AU2018375151B2 (en) | 2025-06-26 |
| JP2021503923A (ja) | 2021-02-15 |
| CA3083354A1 (en) | 2019-06-06 |
| EP3716988A1 (en) | 2020-10-07 |
| JP2023159370A (ja) | 2023-10-31 |
| AU2018375151A1 (en) | 2020-06-11 |
| US20210393700A1 (en) | 2021-12-23 |
| US12233094B2 (en) | 2025-02-25 |
| WO2019108756A1 (en) | 2019-06-06 |
| CN111601606A (zh) | 2020-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250144151A1 (en) | Interaction of fibroblasts and immune cells for activation and uses thereof | |
| US12465621B2 (en) | Mesenchymal stromal cells and uses related thereto | |
| TWI698242B (zh) | 利用血管母細胞產生間葉基質細胞之方法 | |
| DK1926813T3 (en) | Cellepopulationer med immunregulatorisk aktivitet, fremgangsmåde til isolering og anvendelser | |
| ES2769778T3 (es) | Composiciones inmunomoduladoras | |
| US20120269774A1 (en) | Allogeneic stem cell transplants in non-conditioned recipients | |
| US20230226119A1 (en) | Umbilical cord derived regenerative and immune modulatory stem cell populations | |
| US20230295569A1 (en) | Therapeutic regenerative cells | |
| CA3111213A1 (en) | Chimeric antigen receptor fibroblast cells for treatment of cancer | |
| US20230014637A1 (en) | Therapeutic Monocytic Lineage Cells | |
| CN101218341A (zh) | Nk细胞抑制作用用于促进定植的mhc-i阴性细胞持续存在的用途 | |
| US20250375520A1 (en) | Production of immune cells | |
| US20230149523A1 (en) | Treatment of autoimmunity and transplant rejection through establishment and/or promotion of tolerogenic processes by fibroblast-mediated reprogramming of antigen presenting cells | |
| HK40031603A (en) | Interaction of fibroblasts and immune cells for activation and uses thereof | |
| US20230057356A1 (en) | Enhancement of umbilical cord mesenchymal stem cell therapeutic activity by stimulators of t regulatory cells and/or cells expressing cd73 | |
| WO2025125443A1 (en) | Production of immune cells | |
| US20210353685A1 (en) | Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways | |
| Blood | Non-hematopoietic Stem and Progenitor Cells | |
| Atoui | Marrow stromal cells as" universal donor cells" for myocardial regenerative therapy | |
| Class et al. | Patent application title: ALLOGENEIC STEM CELL TRANSPLANTS IN NON-CONDITIONED RECIPIENTS Inventors: Thomas E. Ichim (San Diego, CA, US) Neil H. Riordan (Chandler, AZ, US) Neil H. Riordan (Chandler, AZ, US) Assignees: MEDISTEM LABORATORIES, INC. | |
| NZ563645A (en) | Use of NK cell inhibition to facilitate persistence of engrafted MHC-I negative cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211119 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211119 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220928 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221014 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230106 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230426 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230825 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230825 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230914 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231025 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231115 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7387603 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |